ABSTRACT

Introduction

We evaluated elagolix and leuprolide from the patient’s perspective for the treatment of endometriosis-related pain.

Area covered

Preference weights from a published discrete choice experiment were used to evaluate preferences for treatment profiles simulating elagolix (150 mg/day and 200 mg/twice-daily dosages) and leuprolide for the treatment of moderate to severe endometriosis-related pain. Sensitivity analyses were conducted by varying the range of risk for pregnancy-related problems, moderate to severe hot flashes, and bone fracture across scenarios.

Expert opinion

The 200 mg twice daily dosage of elagolix is more likely to be preferred over leuprolide by patients with moderate to severe endometriosis-related pain in all scenarios explored in the evaluation and sensitivity analyses. The probability that an average respondent would select a treatment was sensitive to increases in risk of moderate to severe hot flashes for leuprolide and possible variations in the risk of pregnancy-related problems for both treatments but was not influenced by an increased risk of bone fracture.

Conclusions

Patients’ preferences for treatment of endometriosis-related pain should be evaluated using the benefits and risks of each pharmacological option. Respondents were more likely to prefer the treatment profile similar to 200 mg twice daily elagolix over that of leuprolide in all scenarios.

中文翻译：

---

美国患者对恶拉戈利和亮丙瑞林治疗子宫内膜异位症相关疼痛的偏好

摘要

介绍

我们从患者的角度评估了恶拉戈利和亮丙瑞林治疗子宫内膜异位症相关疼痛的效果。

覆盖面积

来自已发表的离散选择实验的偏好权重用于评估模拟恶拉戈利（150 毫克/天和 200 毫克/每天两次剂量）和亮丙瑞林治疗中度至重度子宫内膜异位症相关疼痛的治疗方案的偏好。通过改变怀孕相关问题、中度至重度潮热和骨折的风险范围进行敏感性分析。

专家意见

在评估和敏感性分析中探索的所有情况下，中度至重度子宫内膜异位症相关疼痛患者更可能首选 200 mg 每天两次的 elagolix 剂量而不是亮丙瑞林。平均受访者选择治疗的概率对亮丙瑞林中度至重度潮热风险的增加以及两种治疗的妊娠相关问题风险的可能变化敏感，但不受骨折风险增加的影响。

结论

应使用每种药物选择的益处和风险来评估患者对子宫内膜异位症相关疼痛治疗的偏好。在所有情况下，与亮丙瑞林相比，受访者更喜欢类似于每天两次 200 mg elagolix 的治疗方案。